Sven Weiler joins Endogena as VP Medicinal Chemistry

We are pleased to announce that Sven Weiler has joined our team in Schlieren, Switzerland as Vice President Medicinal Chemistry on August 1st, 2022. “I very much look forward to becoming an integral part of Endogena Therapeutics and to extend my expertise among this passionate group of colleagues. It’s exciting to be joining a company […]

Endogena receives Retina Innovation Award at event showcasing new therapies for eye conditions

July 13th, New York, NY Poignantly crafted from the clearest crystal, the Retina Innovation Award that now claims pride of place in Endogena Therapeutics’ trophy cabinet represents how far the company has come in developing a potential new treatment for people losing their sight because of retinitis pigmenosa (RP).  More than 350 international delegates including clinicians, […]

Endogena Therapeutics transitions into clinical stage with its novel regenerative treatment for blindness caused by retinitis pigmentosa

Zürich, Switzerland and Toronto, Canada; 12th July 2022 Endogena Therapeutics Inc. announced today that the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP). RP is a group of inherited diseases causing slow and progressive retinal degeneration and loss of […]

Michael Lai joins Endogena as Medical Director 

As Endogena Therapeutics is moving into the next phase from a pre-clinical to a clinical stage company, we are pleased to announce that Michael Lai has joined our team as Medical Director Clinical Development on April 1st, 2022.   “We are excited to kick-off this critical stage in our company’s development with such a high-profile candidate […]

FDA grants orphan drug designation for Endogena’s lead program targeting retinitis pigmentosa

First small-molecule cell regeneration treatment to be developed for the leading cause of inherited blindness Endogena Therapeutics Inc., which discovers and develops endogenous regenerative medicines, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its EA-2353 ophthalmic suspension targeting retinitis pigmentosa, a rare condition that causes slow and […]

Oversubscribed Series A-1 funding round completed

Endogena Therapeutics closed today their first round of Series A financing, which was capped at $8 million. This first round of Series A financing was led by existing investors, Rejuveron Life Sciences AG and DEFTA Partners, with new investors joining the syndicate. Matthias Steger, CEO of Endogena, said: “This Series A-1 funding will enable us […]

Moreno Menghini appointed chief medical officer

Endogena is very pleased to announce that Dr. Moreno Menghini was appointed as CMO. Dr. Menghini is a vitreoretinal surgeon with clinical trial experience in retinal degeneration and will lead Endogena’s upcoming clinical studies.“I am very excited to be part of the pioneering team at Endogena, and as such be at the forefront of medical innovation.” Dr. Menghini […]